News on DBP from BioPortfolio.com http://www.BioPortfolio.com Consolidated DBP news from BioPortfolio.com Wed, 10 Feb 2010 07:45:17 GMT en A cannabinoid receptor, sensitive to O-1918, is involved in the delayed hypotension induced by anandamide in anaesthetized ratshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3961447&HITNO=0&MSIZE=7&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=DBP&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3961447&THISHREF=http://c.moreover.com/click/here.pl%3fz2496782253%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3961447&HITNO=0&MSIZE=7&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=DBP&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3961447&THISHREF=http://c.moreover.com/click/here.pl%3fz2496782253%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBritish Journal of Pharmacology: Bayer Schering Pharma commences ADVISE in Asia Pacifichttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3962165&HITNO=1&MSIZE=7&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=DBP&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3962165&THISHREF=http://c.moreover.com/click/here.pl%3fz2497075023%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3962165&HITNO=1&MSIZE=7&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=DBP&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3962165&THISHREF=http://c.moreover.com/click/here.pl%3fz2497075023%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBio Spectrum Asia: Observed Changes in Risk during Naturopathic Treatment of Hypertensionhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3948030&HITNO=2&MSIZE=7&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=DBP&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3948030&THISHREF=http://c.moreover.com/click/here.pl%3fz2488409632%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3948030&HITNO=2&MSIZE=7&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=DBP&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3948030&THISHREF=http://c.moreover.com/click/here.pl%3fz2488409632%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMDLinx: Does Coffee Consumption Reduce the Risk of Type 2 Diabetes in Individuals With Impaired Glucose?http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3882368&HITNO=3&MSIZE=7&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=DBP&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3882368&THISHREF=http://c.moreover.com/click/here.pl%3fz2454615958%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3882368&HITNO=3&MSIZE=7&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=DBP&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3882368&THISHREF=http://c.moreover.com/click/here.pl%3fz2454615958%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNational AIDS Treatment Advocacy Project: Second Pivotal Phase III Study of Gilead's Darusentan for Resistant Hypertension Misses Primary Endpointshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3785932&HITNO=4&MSIZE=7&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=DBP&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3785932&THISHREF=http://c.moreover.com/click/here.pl%3fz2402925514%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3785932&HITNO=4&MSIZE=7&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=DBP&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3785932&THISHREF=http://c.moreover.com/click/here.pl%3fz2402925514%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Second Pivotal Phase III Study of Gileads Darusentan for Resistant Hypertension Misses Primary Endpointshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3782666&HITNO=5&MSIZE=7&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=DBP&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3782666&THISHREF=http://c.moreover.com/click/here.pl%3fz2401535894%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3782666&HITNO=5&MSIZE=7&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=DBP&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3782666&THISHREF=http://c.moreover.com/click/here.pl%3fz2401535894%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStockwatch: Second Pivotal Phase III Study of Gilead's Darusentan for Resistant Hypertension Misses Primary Endpointshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3782620&HITNO=6&MSIZE=7&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=DBP&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3782620&THISHREF=http://c.moreover.com/click/here.pl%3fz2401526896%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3782620&HITNO=6&MSIZE=7&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=DBP&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3782620&THISHREF=http://c.moreover.com/click/here.pl%3fz2401526896%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBusiness Wire via Yahoo!: